News & Blog

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy

Meet the Community – Gabriel Queiroz Pereira & Fernanda Cenci Queiroz

rideATAXIA Gainesville 2024 Recap

Meet the Community – Joe Tyler

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

March 2024 – Advocacy Newsletter

Meet the Community – Rina

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia

Meet the Community – Dylan Helms

FA Community Update from Biogen

Meet the Community – David Layton Jr

February 2024 – Advocacy Newsletter